Efficacy of Stereotactic Body Radiotherapy for Recurrent or Residual Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization

• Published in: BioMed research international Vol. 2018; no. 2018; pp. 1 - 6
• Main Authors: Wu, Fasheng, Lin, Lianxing, Liu, Jianmin, Huang, Hecheng, Han, Fei, Wu, Xianheng, Zheng, Yinyan, Zhao, Xiaofang, Chen, Jinghong, Yao, Erhua, Liang, Ping
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Publishing Corporation 01.01.2018; Hindawi; John Wiley & Sons, Inc
• Subjects: Adult; Aged; Cancer therapies; Carcinoma, Hepatocellular - mortality; Carcinoma, Hepatocellular - radiotherapy; Care and treatment; Chemoembolization, Therapeutic - methods; Combined Modality Therapy - methods; Drug dosages; Fatigue; Female; Gastroenterology; Hepatitis; Hepatocellular carcinoma; Hepatology; Hepatoma; Humans; Lesions; Liver cancer; Liver cirrhosis; Liver Neoplasms - mortality; Liver Neoplasms - radiotherapy; Male; Metastasis; Middle Aged; Patients; Radiation therapy; Radiosurgery - methods; Radiotherapy; Retrospective Studies; Spinal cord; Survival; Survival analysis; Survival Rate; Toxicity; Treatment Outcome; China; United States > US; Europe

Aim. To evaluate the efficacy and toxicity of hypofractionated stereotactic body radiotherapy (SBRT) for patients with recurrent or residual hepatocellular carcinoma (HCC) after transcatheter arterial chemoembolization (TACE). Methods. Between June 2008 and July 2015, thirty-three patients with HCC...